Author:
Pramanti Arsenila D.,Barliana Melisa I.,Lestari Keri
Abstract
COVID-19 has developed into a public health emergency of international concern and is a major threat to global health. Several studies have been conducted with the aim of dampening the inflammatory response in COVID-19 patients. To dampen the cytokine storm, some therapies immunotargeting IL-1, IL-2, IL-6, and TNFα are being evaluated and one of the promising immune modulators is mesenchymal stem cells (MSCs). MSCs have the beneficial effect of preventing or attenuating cytokine storms by secreting potent anti-inflammatory factors and addressing the severity of the COVID-19 infection.
This study examines the mesenchymal stem cells for the treatment of patients with COVID-19 severe/critical category.
This literature review outlines the therapeutic effectiveness of MSCs in the treatment of COVID-19 in the critically ill patient category.
Several research showed that the administration of MSC therapy in COVID-19 patients has significant clinical improvement results, normalized the vital signs of patients, reduced the severity and reduced mortality. In addition, overall treatment with MCS did not cause side effects.
Publisher
Bentham Science Publishers Ltd.
Reference42 articles.
1. Zhou P, Yang XL, Wang XG, et al.
A pneumonia outbreak associated with a new coronavirus of probable bat origin.
Nature
2020;
579
(7798)
: 270-3.
2. Taylor D, Lindsay AC, Halcox JP.
Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1.
N Engl J Med
2010;
382
(16)
: 1564-7.
3. Daniels LB, Ren J, Kumar K, et al.
Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: Findings from the American Heart Association’s COVID-19 Cardiovascular Disease Registry.
PLoS One
2021;
16
(7)
: e0254635.
4. WHO.
Coronavirus Disease 2019 situation report 51 - 11th March 2020.
Bull World Health Organ
2020;
2019
(March)
: 2633.
5. Tolksdorf K, Buda S, Schuler E, Wieler LH, Haas W.
Influenza-associated pneumonia as reference to assess seriousness of coronavirus disease (COVID-19).
Euro Surveill
2020;
25
(11)
: 1-5.